Serial #86836956
LIVE

Serial Number

86836956

Owner

Seqirus UK Limited

Attorney

Nancy Sabarra

Filing Date

Dec 2, 2015

Add to watchlist:

No watchlists yet
View on USPTO

Serial #86836956 Trademark

Serial Number: 86836956 • Registration: 5420871

Serial #86836956 is a trademark filed by Seqirus UK Limited on December 2, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Seqirus UK Limited (138 trademarks)

Point, 29 Market Street

Entity Type: 98

Trademark Details

Filing Date

December 2, 2015

Registration Date

March 13, 2018

Published for Opposition

June 6, 2017

Goods & Services

Vaccines; [ medicated serums for the treatment of influenza; antibodies for medical use, namely, immunoglobulins; ] influenza vaccines; [ adjuvants for medical purposes for use with vaccines and for immunological purposes; pharmaceutical substances in the nature of antigens, namely, antigen vaccines, antigens for the treatment of influenza, and antigens for development of third party pharmaceutical and immunological products; ] pharmaceutical preparations and substances for the [ treatment and/or ] prevention of [ blood or bleeding disorders, or ] diseases caused [ by bacteria and ] viruses [ ; blood products for medical use, namely, blood plasma, reagent blood cells; products derived from blood and products derived from recombinant DNA technology, namely, immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for medical therapeutic use; medicated serums, namely, anti-venoms for treatment of bites and stings; medicated serums for the treatment of blood or bleeding disorders; test kits, namely, invitro diagnostic reagent test kits for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, Rheysys Factor D Antigen reagents for the detection of specific antigens or in blood typing; pharmaceutical preparations, namely, reagent red blood cells used to detect antibodies or immunoglobulin subtypes; pharmaceutical preparations, namely, monoclonal and polyclonal antibodies; pharmaceutical preparations, namely, reagents for medical/clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes ]

[ Chemical and biological reagents for scientific use and/or for non-medical purposes; cell cultures and media for scientific use and/or for non-medical purposes; chemical test kits for scientific and laboratory use for anti-body screening, blood grouping or for detection of specific blood cells, antigens or immunoglobulin subtypes; chemical preparations for scientific and/or industrial purposes; diagnostic reagents for scientific use; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for anti-body screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells ]

[ Medical services; medical information services; health care services, namely, nursing services; health care information services; health care services, namely, medical services in the nature of patient support services and programs; health care services, namely, medical services in the nature of providing medical information concerning blood products, and providing medical information concerning vaccines, anti-venoms and immunohematology products in the nature of diagnostic reagents; medical services, namely, patient support services in the nature of providing medical information, including patient medical information, via an internet database, where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community ]

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Apr 4, 2025 NAS8
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
Apr 4, 2025 8.PR
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 4, 2025 APRE
TEAS SECTION 8 RECEIVED
Sep 9, 2024 ES8R
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Mar 13, 2023 REM1
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 25, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 25, 2019 REAP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 18, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 18, 2018 REAP
REGISTERED-PRINCIPAL REGISTER
Mar 13, 2018 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Feb 5, 2018 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 5, 2018 AITU
NOTICE OF ALLOWANCE CANCELLED
Jan 25, 2018 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Jan 25, 2018 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 1, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 6, 2017 NPUB
PUBLISHED FOR OPPOSITION
Jun 6, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 17, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 4, 2017 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 25, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 19, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 19, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 19, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 14, 2017 GNRN
NON-FINAL ACTION E-MAILED
Mar 14, 2017 GNRT
NON-FINAL ACTION WRITTEN
Mar 14, 2017 CNRT
NON-FINAL ACTION WRITTEN
Mar 14, 2017 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 16, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 16, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 14, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 21, 2016 GNRN
NON-FINAL ACTION E-MAILED
Oct 21, 2016 GNRT
NON-FINAL ACTION WRITTEN
Oct 21, 2016 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 30, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 30, 2016 CRFA
ASSIGNED TO LIE
Sep 29, 2016 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 15, 2016 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 1, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 1, 2016 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 25, 2016 GNRN
NON-FINAL ACTION E-MAILED
Mar 25, 2016 GNRT
NON-FINAL ACTION WRITTEN
Mar 25, 2016 CNRT
ASSIGNED TO EXAMINER
Mar 21, 2016 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Dec 8, 2015 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 7, 2015 NWOS
NEW APPLICATION ENTERED
Dec 5, 2015 NWAP